Today: 9 June 2026
Browse Category

NYSE:BUD 19 October 2025 - 26 January 2026

AB InBev snaps up Live Nation UK beer deal, putting Budweiser and Stella Artois in the festival spotlight

AB InBev snaps up Live Nation UK beer deal, putting Budweiser and Stella Artois in the festival spotlight

AB InBev has signed an exclusive partnership with Live Nation UK, making its beer and cider brands the sole options at over 20 festivals and all Academy Music Group venues. Budweiser, Corona, San Miguel, and Stella Artois will feature at events including Reading & Leeds and London’s O2 Academy Brixton. AB InBev shares traded at 58.88 euros, up 28% year-on-year, but analysts cited debt and execution risks.
26 January 2026
·
AB InBev (BUD) Today — Nov. 11, 2025: Morgan Stanley Trims Price Target as Buyback Progresses; DZ Bank Reiterates ‘Buy’ and Valuation Debates Heat Up

AB InBev (BUD) Today — Nov. 11, 2025: Morgan Stanley Trims Price Target as Buyback Progresses; DZ Bank Reiterates ‘Buy’ and Valuation Debates Heat Up

Morgan Stanley lowered its 12-month price target for AB InBev to $79 from $81.50 but kept an Overweight rating, citing weaker volume forecasts into 2026. AB InBev bought back 1,150,019 shares for €62 million between Nov. 3–7 under its new $6 billion buyback program. DZ Bank reiterated Buy on Nov. 8. Analyst consensus remains Moderate Buy, with average targets in the low $70s.
11 November 2025
·
Netflix Stock Soars to Record Highs Amid Bold Deals and Streaming War Shake-Up

Netflix Stock Soars to Record Highs Amid Bold Deals and Streaming War Shake-Up

Netflix shares have surged about 70% in the past year, trading near $1,200 and sitting roughly 10% below their all-time high ahead of Q3 earnings on October 21. The company now reports over 300 million paid subscribers, with its ad-supported tier reaching more than 94 million users globally. Netflix will stream a live NFL game on Christmas Day and has announced a partnership with AB InBev for live event advertising.
19 October 2025
······

Stock Market Today

  • NSE Allocates 10% of Annual CSR Fund to Social Stock Exchange
    June 9, 2026, 10:16 AM EDT. The National Stock Exchange (NSE) will deploy 10% of its annual Corporate Social Responsibility (CSR) corpus through the Social Stock Exchange, signaling trust in this market-based platform designed to connect social enterprises with investors. This move aims to enhance transparency and impact investing by leveraging the exchange's resources to support social causes.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Go toTop